We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About OtoNexus Medical Technologies Stock

Invest in or calculate the value of your shares in OtoNexus Medical Technologies or other pre-IPO companies through EquityZen's platform.

Get Started

OtoNexus Medical Technologies Stock (OTMT)

OtoNexus Medical Technologies commercializes a patented medical device designed to diagnose middle ear infections.

About OtoNexus Medical Technologies Stock

Founded

2010

Headquarters

Bellevue, WA, US

Industries

Software, Artificial Intelligence, Data and Analytics

OtoNexus Medical Technologies commercializes a patented medical device designed to diagnose middle ear infections in children and adults. It will allow clinicians to accurately identify viral vs. bacterial infection and determine whether an antibiotic is appropriate. The device applies a well-known medical technology, ultrasound, in a completely novel way to achieve a key advance in the detection of otitis media. One-use-per-patient tips create a recurring revenue stream. The device will provide data in seconds and will be easy to use by physicians or non-physician personnel (NPs, PAs).

OtoNexus Medical Technologies Management

Leadership team at OtoNexus Medical Technologies

Chief Executive Officer, Co-Founder

Caitlin Cameron

Co-Founder and Chief Science Officer

Mark A. Moehring

Locked Features

Join now and verify your accreditation status to gain access to:

  • OtoNexus Medical Technologies current valuation
  • OtoNexus Medical Technologies stock price
  • Available deals in OtoNexus Medical Technologies and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in OtoNexus Medical Technologies stock?

Accredited investors can buy pre-IPO stock in companies like OtoNexus Medical Technologies through EquityZen funds. These investments are made available by existing OtoNexus Medical Technologies shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell OtoNexus Medical Technologies stock?

Shareholders can sell their OtoNexus Medical Technologies stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."